{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:44:23Z","timestamp":1790628263084,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00417-024-06599-3","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T13:03:13Z","timestamp":1723554193000},"page":"225-230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Teprotumumab for thyroid eye disease in patients with hypothyroid\/euthyroid state: a multicenter case series"],"prefix":"10.1007","volume":"263","author":[{"given":"Shoaib","family":"Ugradar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuil","family":"Parunakian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Malkhasyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pershanjit","family":"Raika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Tolentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Kossler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Cockerham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"Amarikwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond S.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"6599_CR1","doi-asserted-by":"publisher","unstructured":"Mu\u00f1oz-Ortiz J, Sierra-Cote MC, Zapata-Bravo E et al (2020) Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: a systematic review of the literature. Syst Reviews 9. https:\/\/doi.org\/10.1186\/S13643-020-01459-7","DOI":"10.1186\/S13643-020-01459-7"},{"key":"6599_CR2","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/EYE.2011.186","volume":"25","author":"MB Kashkouli","year":"2011","unstructured":"Kashkouli MB, Pakdel F, Kiavash V et al (2011) Hyperthyroid vs hypothyroid eye disease: the same severity and activity. Eye 25:1442. https:\/\/doi.org\/10.1038\/EYE.2011.186","journal-title":"Eye"},{"key":"6599_CR3","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/BJO.2007.137265","volume":"93","author":"AK Eckstein","year":"2009","unstructured":"Eckstein AK, L\u00f6sch C, Glowacka D et al (2009) Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J Ophthalmol 93:1052\u20131056. https:\/\/doi.org\/10.1136\/BJO.2007.137265","journal-title":"Br J Ophthalmol"},{"key":"6599_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01258-w","author":"P Perros","year":"2020","unstructured":"Perros P, \u017darkovi\u0107 MP, Panagiotou GC et al (2020) Asymmetry indicates more severe and active disease in Graves\u2019 orbitopathy: results from a prospective cross-sectional multicentre study. J Endocrinol Investig. https:\/\/doi.org\/10.1007\/s40618-020-01258-w","journal-title":"J Endocrinol Investig"},{"key":"6599_CR5","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","volume":"181","author":"S Tsui","year":"2008","unstructured":"Tsui S, Naik V, Hoa N et al (2008) Evidence for an association between thyroid-stimulating hormone and insulin-like Growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 Disease. J Immunol 181:4397\u20134405. https:\/\/doi.org\/10.4049\/jimmunol.181.6.4397","journal-title":"J Immunol"},{"key":"6599_CR6","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1210\/jc.2014-3566","volume":"100","author":"CC Krieger","year":"2015","unstructured":"Krieger CC, Neumann S, Place RF et al (2015) Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves\u2019 disease immunoglobins. J Clin Endocrinol Metab 100:1071\u20131077. https:\/\/doi.org\/10.1210\/jc.2014-3566","journal-title":"J Clin Endocrinol Metab"},{"key":"6599_CR7","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1210\/jc.2004-0716","volume":"89","author":"TJ Smith","year":"2004","unstructured":"Smith TJ, Hoa N (2004) Immunoglobulins from patients with graves\u2019 disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab 89:5076\u20135080. https:\/\/doi.org\/10.1210\/jc.2004-0716","journal-title":"J Clin Endocrinol Metab"},{"key":"6599_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s11910-012-0256-9","volume":"12","author":"EF Gillespie","year":"2012","unstructured":"Gillespie EF, Smith TJ, Douglas RS (2012) Thyroid eye disease: towards an evidence base for treatment in the 21st century. Curr Neurol Neurosci Rep 12:318\u2013324. https:\/\/doi.org\/10.1007\/s11910-012-0256-9","journal-title":"Curr Neurol Neurosci Rep"},{"key":"6599_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40265-020-01287-y","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A (2020) Teprotumumab: first approval. Drugs 80:509\u2013512","journal-title":"Drugs"},{"key":"6599_CR10","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG et al (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376:1748\u20131761. https:\/\/doi.org\/10.1056\/NEJMoa1614949","journal-title":"N Engl J Med"},{"key":"6599_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/S41433-021-01593-Z","author":"U S","year":"2021","unstructured":"S U, AL JK K, et al (2021) Teprotumumab for the treatment of chronic thyroid eye disease. Eye. https:\/\/doi.org\/10.1038\/S41433-021-01593-Z","journal-title":"Eye"},{"key":"6599_CR12","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L et al (2021) The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol 185:G43\u2013G67. https:\/\/doi.org\/10.1530\/EJE-21-0479","journal-title":"Eur J Endocrinol"},{"key":"6599_CR13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/bjo.73.8.639","volume":"73","author":"MP Mourits","year":"1989","unstructured":"Mourits MP, Koornneef L, Wiersinga WM et al (1989) Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach. Br J Ophthalmol 73:639\u2013644","journal-title":"Br J Ophthalmol"},{"key":"6599_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A et al (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382:341\u2013352. https:\/\/doi.org\/10.1056\/NEJMoa1910434","journal-title":"N Engl J Med"},{"key":"6599_CR15","doi-asserted-by":"publisher","unstructured":"Ugradar S, Shi L, Wang Y et al (2020) Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. https:\/\/doi.org\/10.1038\/s41433-020-01297-w. Eye (Basingstoke)","DOI":"10.1038\/s41433-020-01297-w"},{"key":"6599_CR16","doi-asserted-by":"publisher","first-page":"942","DOI":"10.4049\/jimmunol.168.2.942","volume":"168","author":"J Pritchard","year":"2002","unstructured":"Pritchard J, Horst N, Cruikshank W, Smith TJ (2002) Igs from patients with Graves\u2019 Disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol 168:942\u2013950. https:\/\/doi.org\/10.4049\/jimmunol.168.2.942","journal-title":"J Immunol"},{"key":"6599_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/01676830490504089","volume":"23","author":"MP Mourits","year":"2004","unstructured":"Mourits MP, Lombardo SHC, Van Der Sluijs FA, Fenton S (2004) Reliability of exophthalmos measurement and the exophthalmometry value distribution in a healthy Dutch population and in Graves\u2019 patients. An exploratory study. Orbit 23:161\u2013168. https:\/\/doi.org\/10.1080\/01676830490504089","journal-title":"Orbit"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06599-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-024-06599-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06599-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T05:50:39Z","timestamp":1738993839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-024-06599-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["6599"],"URL":"https:\/\/doi.org\/10.1007\/s00417-024-06599-3","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"11 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was provided by the following institutions: private practice of Dr. Raymond Douglas, Byers Eye Institute, private practice of Dr. Kimberly Cockerham, and Concord Eye Center. All procedures performed in studies involving human participants were in accordance with the ethical standards of the private practice of Dr. Raymond Douglas, Byers Eye Institute, private practice of Dr. Kimberly Cockerham, Concord Eye Center, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by all the sites\u2019 institutional review boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Shoaib Ugradar is consultant for Jenssen, Acelyrin, and Viridian Therapeutics, previous consultant for Amgen. Raymond Douglas is an employee of Sling Therapeutics. Kimberly Cockerham is a consultant for Amgen (formerly Horizon Therapeutics), Viridian Pharmaceuticals and 3T Ophthalmics. Andrea Kossler is a consultant for Amgen (Horizon Therapeutics). David Weinberg is a consultant for Amgen (formerly Horizon Therapeutics). All other authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}